17 results about "HUMAN THYMUS" patented technology

The invention discloses a breast adenoma B3 type source cell strain as well as construction and application thereof, the breast adenoma B3 type source cell strain is named as human breast adenoma cell Hthy2301 Homo sapiens and is preserved in China Center for Type Culture Collection on March 14, 2024, and the preservation number is CCTCC NO: C202478. The human thymoma cell line is stable in character, can be passaged in vitro for a long time, and has high proliferation activity. The human thymoma cell line disclosed by the invention can be used as an effective cell model, and a new experimental model can be provided for deeply researching the occurrence, development and transfer mechanisms of thymoma, the drug resistance mechanism, drug screening, drug effect evaluation and the like.

The invention relates to a human thymus primary cell separation kit and a separation method, the kit comprises an extraction reagent for preparing a thymus tissue single-cell suspension and a separation reagent for purification, and by combining the reagents in the kit and matching with corresponding operation steps, the human thymus primary cell can be separated. And one or a combination of more of thymus epithelial cells, thymus dendritic cells, thymus T cells and thymus B cells can be accurately extracted from human thymus tissues. The method has the beneficial effects that the target primary cells in the thymus tissue sample can be separated, the specificity is high, different primary cell components can be separated through one-time operation by combining different reagents, and various target primary cells with relatively high purity are obtained; and the success rate of separating the primary cell component in the thymus tissue sample by using the method is as high as 90%, and the sample loss is reduced.

Disclosed in the present invention are an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), a preparation method therefor and an application thereof. The anti-hTSLP antibody of the present invention can specifically bind to a hTSLP receptor, has a good effect of inhibiting the secretion of TARC by PBMC, and can be applied to the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.

Provided in the present invention are an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and the use thereof. The monoclonal antibody has high affinity for human TSLP, has a neutralizing activity, and can be used for preventing or treating TSLP-mediated diseases.

Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and / or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocytes. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable the use of this product in medical applications.

In an aspect, a method of making a humanized animal includes providing an immune-deficient animal lacking mature T cells, B cells and NK cells; and injecting a population of human thymocytes into the immune-deficient animal to provide the humanized animal; wherein the population of human thymocytes are thymocytes collected from human thymus or thymus tissue; and wherein the humanized animal includes mature human T cells expressing human CD8 and human CD4. In another aspect, also included is a humanized animal prepared by the foregoing method.

The application belongs to the technical field of biological medicine, and particularly relates to a recombinant human thymosin beta 4 microneedle patch, a preparation method thereof and application. After a microneedle solution and a support layer solution are obtained, the microneedle solution is added into a microneedle mold, and then exhaust treatment is performed; after the exhaust treatment, the support layer solution is added into the microneedle mold to obtain a formed body; the formed body is dried, and after demolding, the recombinant human thymosin beta 4 microneedle patch is obtained; the temperature of the drying is < 40 DEG C. The recombinant human thymosin beta 4 microneedle patch prepared by the application has high drug loading, good forming, and high mechanical strength, can rapidly and continuously release most of the drugs in a short time, is beneficial to the percutaneous penetration of the Tbeta4 drug, and has a good promoting effect on wound healing.

Age-related thymic involution is a major cause of immunosenescence, characterized by reduced T-cell production, resulting in increased susceptibility to cancers, infections, autoimmunity and reduced vaccine efficacy. RANK / RANKL axis in the thymus is altered during aging and endothelial cells (EC) depend on RANK for their cellularity and functional maturation. Decreased RANKL availability during aging results in a decline in cellularity and function of EC and thymic epithelial cells (TEC) leading to thymic involution. Whereas RANKL neutralization in young mice mimics thymic involution, RANKL cytokine treatment in aged mice restores thymic architecture, EC and TEC cellularity and functional properties. Consequently, RANKL improves T-cell progenitor homing to the thymus and boosts T-cell production. This cascade of events results in peripheral T-cell renewal and effective anti-tumor and vaccine responses. RANKL stimulates EC and TEC in human thymic organo-cultures and is the basis of a treatment that rejuvenates thymic function and improves T-cell immunity in the elderly.

The invention belongs to the technical field of thymus immigration cell detection, and particularly relates to a thymus immigration cell marker and application thereof, the marker comprises CD38 used for representing CD4RTE and CD8RTE, the CD38 can be used as a marker for defining thymus RTE, and a system and a kit for detecting the output function of thymus by CD3 + CD4 + CD45RA + CCR7 + CD31 + CD38 + and CD3 + CD8 + CD45RA + CCR7 + CD38 + cells are provided. Compared with the prior art, the thymus output function is detected more quickly and effortlessly, human peripheral CD4RTE can be more accurately defined by detecting the expression of the T cells CD31 and CD38, human peripheral CD8RTE cells can be more accurately defined by detecting the expression of the T cells CD38, and the CD38 can be used as a new surface molecular marker of the CD8RTE. The discovery of the CD8RTE marker supplements the existing theory, and is beneficial to the evaluation of the human thymus senescence function.

The present application relates to the technical field of biology, in particular to human thymus tissue digestion solution and application thereof. The present application provides a preparation method of human thymus tissue digestion solution and human thymus tissue single cells, and the preparation method can obtain a human thymus tissue primary cell suspension with high viability, low fine nodule rate, high nucleated rate and less impurities, and can greatly improve the success rate of single cell sequencing experiment of human thymus tissue primary cells.

Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and / or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocytes. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable the use of this product in medical applications.

Methods of differentiating pluripotent stem cells into thymic epithelial progenitor cells are provided.

This invention provides a human anti-thymocyte globulin (ATG) product, as well as a method for producing and using the same. [Solution] This disclosure provides polyclonal immunoglobulins derived from ungulates having a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds to human thymocytes, T cells, B cells, and / or monocytes. Such compositions can be produced by immunizing transgenic animals having the human Ig locus with human thymocytes. This method produces polyclonal immunoglobulins with yield, purity, and antigen specificity that enable the use of this product in medical applications.

The present application provides an antibody molecule binding to human thymic stromal lymphopoietin (TSLP) and antigen-binding fragments thereof, and use of the antibody molecule or antigen-binding fragments thereof for preventing or treating TSLP high expression related purposes. The antibody molecule and antigen-binding fragments thereof of the present application can bind to human TSLP with high affinity, block the interaction between TSLP and its receptor, and significantly inhibit the secretion of chemokines such as CCL17, OPG, and dendritic cells, and can be used for treating diseases and disorders related to TSLP signaling and / or TSLP cell expression, such as inflammatory diseases or tumors.

The present application provides a method for identifying an anti-human thymic stromal lymphopoietin (TSLP) bispecific antibody having a function capable of blocking the binding of human thymic stromal lymphopoietin (TSLP) to human TSLP receptor (TSLPR) and capable of blocking the binding of human IL-7 receptor alpha chain (IL-7R alpha) to human TSLP: TSLPR complex.

The invention relates to a human thymoma cell line capable of expressing enhanced green fluorescent protein and a preparation method thereof, EGFP is used as target green fluorescent protein, a sequence with multiple cloning sites is obtained through design and optimization, the sequence is inserted into a lentiviral expression vector, then EGFP is inserted into the lentiviral expression vector, fluorescent recombinant lentivirus containing the multiple cloning sites is prepared, and the human thymoma cell line capable of expressing the enhanced green fluorescent protein is obtained. And transfecting a thymoma cell line with the EGFP gene to obtain the thymoma cell line capable of efficiently expressing the EGFP. The cell line can be better used as a fluorescent tool, green fluorescent protein EGFP is obtained through stable expression, and the recombinant lentivirus fluorescent vector contains 10 multiple cloning sites, so that subsequent insertion of related genes is facilitated, and a valuable lentivirus vector tool is provided for research on regulation and control of more genes in thymoma.

The present invention discloses an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), as well as methods for preparing and using the same. The anti-human TSLP antibody of the present invention can specifically bind to the human TSLP receptor and has a potent inhibitory effect on TARC secretion by PBMCs, making it suitable for the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.